keyword
MENU ▼
Read by QxMD icon Read
search

Biochemical relapse of prostate cancer

keyword
https://www.readbyqxmd.com/read/29339090/patched-1-expression-correlates-with-biochemical-relapse-in-high-risk-prostate-cancer-patients
#1
Annelies Gonnissen, Sofie Isebaert, Christiaan Perneel, Chad M McKee, Filip Van Utterbeeck, Evelyne Lerut, Clare Verrill, Richard J Bryant, Steven Joniau, Ruth J Muschel, Karin Haustermans
There is an unmet clinical need for adequate biomarkers to aid risk stratification and management of prostate cancer (PCa) patients. Even within the high-risk PCa category not all patients will invariably have a poor prognosis, and improved stratification of this heterogeneous group is needed. In this context, components of the hedgehog (Hh) pathway may have promise as biomarkers, as the available evidence suggests increased Hh pathway activity may confer a poorer outcome in advanced and castrate-resistant PCa...
January 12, 2018: American Journal of Pathology
https://www.readbyqxmd.com/read/29337395/testosterone-suppression-with-luteinizing-hormone-releasing-hormone-lhrh-agonists-in-patients-receiving-radiotherapy-for-prostate-cancer
#2
Derek Wilke, Nikhilesh Patil, Helmut Hollenhorst, David Bowes, Robert Rutledge, Casely Ago
OBJECTIVES: To characterize the probability of testosterone escape during a course of radiotherapy and androgen deprivation (ADT) in patients with prostate cancer, and examine predictors of testosterone escape, the prostate specific antigen (PSA) levels during testosterone escape, and the impact of testosterone escape on outcome. PATIENTS AND METHODS: To participate in the database review, necessary data included: (i) type of luteinizing hormone-releasing hormone agonist (LHRHa) administered, date of initiation, and date of cessation or duration of therapy, (ii) radiotherapy information (start date and dose) with at least 6 months of follow-up after radiotherapy, (iii) had to have radiotherapy to the prostate or prostate bed, and (iv) had to have a least one serum testosterone and PSA measurement...
January 16, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29319928/low-dose-rate-brachytherapy-for-prostate-cancer-outcomes-beyond-10-years-of-follow-up
#3
S Lazarev, M R Thompson, N N Stone, R G Stock
OBJECTIVES: To examine biochemical control, survival, and late morbidity with definitive low-dose-rate brachytherapy (LDR-BT) for prostate cancer patients surviving ≥10 years post-treatment. MATERIALS AND METHODS: We identified 757 men with localized prostate cancer who underwent definitive LDR-BT in the period 1990-2006 and were followed for ≥10 years at our institution. Biochemical failure-free survival (BFFS), distant metastases-free survival (DMFS), disease-specific survival (DSS), and overall survival (OS) were selected as study endpoints...
January 10, 2018: BJU International
https://www.readbyqxmd.com/read/29315174/oligorecurrent-nodal-prostate-cancer-long-term-results-of-an-elective-nodal-irradiation-approach
#4
Sebastien Tran, Sandra Jorcano, Teresa Falco, Giorgio Lamanna, Raymond Miralbell, Thomas Zilli
OBJECTIVES: The objective of this study was to report long-term results of elective nodal radiotherapy (ENRT) in prostate cancer (PCa) patients with oligorecurrent nodal disease after primary treatment. METHODS: Data of 53 oligorecurrent PCa patients (N1 and/or M1a) with ≤5 nodal metastases (n=108) treated with ENRT combined with androgen deprivation therapy (ADT) between 2004 and 2016 were retrospectively reviewed. Median prostate-specific antigen (PSA) and PSA doubling time (DT) were 3...
January 8, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29290572/phase-1-2-study-of-hypofractionated-intensity-modulated-radiation-therapy-for-prostate-cancer-including-simultaneously-integrated-boost
#5
Michael G Chang, Nitai Mukhopadhyay, Diane Holdford, Vicki Skinner, Siddharth Saraiya, Drew Moghanaki, Mitchell S Anscher
PURPOSE: This study evaluates the safety and efficacy of moderately hypofractionated radiation therapy (RT) with simultaneous integrated boost (HSIB) intensity modulated RT (IMRT) that includes coverage of the seminal vesicles (SVs) and pelvic lymph nodes (LNs). METHODS AND MATERIALS: Men with localized prostate cancer were prospectively enrolled in a phase 1/2 trial to receive HSIB-IMRT to the prostate, ± SV, ± pelvic LN using a risk-based method. Low-risk patients received 69...
September 18, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/29282518/current-status-of-theranostics-in-prostate-cancer
#6
REVIEW
Irene Virgolini, Clemens Decristoforo, Alexander Haug, Stefano Fanti, Christian Uprimny
The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of 68Ga-PSMA-directed PET imaging as a diagnostic procedure for primary and recurrent PC as well as the role of evolving PSMA radioligand therapy (PRLT) in castration-resistant (CR)PC is assessed. The most eminent data from mostly retrospective studies currently available on theranostics of prostate cancer are discussed. The current knowledge on 68Ga-PSMA PET/CT implicates that primary staging with PET/CT is meaningful in patients with high-risk PC and that the combination with pelvic multi parametric (mp)MR (or PET/mpMR) reaches the highest impact on patient management...
December 28, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29275507/a-12-year-follow-up-of-anna-c-trus-image-targeted-biopsies-in-patients-suspicious-for-prostate-cancer
#7
Theodoros Tokas, Björn Grabski, Udo Paul, Leif Bäurle, Tillmann Loch
PURPOSE: PSA screening has been rehabilitated. PSA is not specific and can be elevated by benign reasons. Additionally, a subgroup of patients with prostate hyperplasia may harbor prostate cancer (PCa). During monitoring, the clinician aims to detect significant tumors in time, submitting patients to minimal psychological and physical burden, especially in men with high serum PSA and repeat biopsies. We aimed to determine long-term outcomes with respect to ANNA/C-TRUS ability to detect PCa with six targeted biopsies...
December 23, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29249526/curative-radiation-therapy-at-time-of-progression-under-active-surveillance-compared-with-up-front-radical-radiation-therapy-for-prostate-cancer
#8
Alejandro Berlin, Ardalan E Ahmad, Melvin L K Chua, Fabio Y Moraes, Haiyan Jiang, Maria Komisarenko, Narhari Trimilshina, Hamid Raziee, Ali Hosni, Jure Murgic, Peter Chung, Robert G Bristow, Antonio Finelli
PURPOSE: To describe and compare outcomes in men with initially presumed indolent prostate cancer receiving definitive radiation therapy after active surveillance (AS) versus those in a risk-matched cohort undergoing up-front radiation therapy. METHODS AND MATERIALS: Men prospectively enrolled in an AS program between 1992 and 2014 and subsequently undergoing curative radiation therapy (ie, image guided radiation therapy [IGRT] or low-dose-rate brachytherapy [LDR-BT]) were identified...
November 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29208480/robotic-stereotactic-retreatment-for-biochemical-control-in-previously-irradiated-patients-affected-by-recurrent-prostate-cancer
#9
M Loi, V Di Cataldo, G Simontacchi, B Detti, P Bonomo, L Masi, I Desideri, D Greto, G Francolini, V Carfora, D Pezzulla, M Perna, G A Carta, L Livi
AIMS: Robotic stereotactic body radiotherapy (rSBRT) to local recurrences emerged as a valuable option for exclusive local failure after prior external beam radiation therapy (EBRT) for localised prostate cancer. The aim of this study was to assess the efficacy and safety of rSBRT in patients experiencing locally recurrent prostate cancer after prior definitive or postoperative radiotherapy using the Cyberknife. MATERIALS AND METHODS: Data from 50 patients were retrospectively reviewed...
December 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29194951/quantification-of-large-scale-dna-organization-for-predicting-prostate-cancer-recurrence
#10
Calum MacAulay, Mira Keyes, Malcolm Hayes, Andrea Lo, Gang Wang, Martial Guillaud, Martin Gleave, Laden Fazli, Jagoda Korbelik, Colin Collins, Sarah Keyes, Branko Palcic
This study investigates whether Genomic Organization at Large Scales (which we propose to call GOALS) as quantified via nuclear phenotype characteristics and cell sociology features (describing cell organization within tissue) collected from prostate tissue microarrays (TMAs) can separate biochemical failure from biochemical nonevidence of disease (BNED) after radical prostatectomy (RP). Of the 78 prostate cancer tissue cores collected from patients treated with RP, 16 who developed biochemical relapse (failure group) and 16 who were BNED patients (nonfailure group) were included in the analyses (36 cores from 32 patients)...
November 30, 2017: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/29192364/liver-metastases-from-prostate-cancer-at-11c-choline-pet-ct-a-multicenter-retrospective-analysis
#11
Pietro Ghedini, I Bossert, L Zanoni, F Ceci, T Graziani, P Castellucci, V Ambrosini, F Massari, E Nobili, B Melotti, A Musto, S Zoboli, L Antunovic, M Kirienko, A Chiti, C Mosconi, A Ardizzoni, R Golfieri, S Fanti, C Nanni
AIM: During our daily clinical practice using 11C-Choline PET/CT for restaging patients affected by relapsing prostate cancer (rPCa) we noticed an unusual but significant occurrence of hypodense hepatic lesions with a different tracer uptake. Thus, we decided to evaluate the possible correlation between rPCa and these lesions as possible hepatic metastases. MATERIALS AND METHODS: We retrospectively enrolled 542 patients diagnosed with rPCa in biochemical relapse after a radical treatment (surgery and/or radiotherapy)...
November 30, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29176717/high-mir-205-expression-in-normal-epithelium-is-associated-with-biochemical-failure-an-argument-for-epithelial-crosstalk-in-prostate-cancer
#12
Yngve Nordby, Elin Richardsen, Nora Ness, Tom Donnem, Hiten R H Patel, Lill-Tove Busund, Roy M Bremnes, Sigve Andersen
Due to insufficient prognostic tools, failure to predict aggressive prostate cancer (PC) has left patient selection for radical treatment an unsolved challenge. This has resulted in overtreatment with radical therapy. Better prognostic tools are urgently warranted. MicroRNAs (miRs) have emerged as important regulators of cellular pathways, resulting in altered gene expressions. miR-205 has previously been observed downregulated in PC, acting as tumor suppressor. Herein, the expression of miR-205 in prostate tissue was examined in a large, well-described cohort of 535 Norwegian prostatectomy patients...
November 24, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29166142/effects-of-dose-escalated-radiotherapy-in-combination-with-long-term-androgen-deprivation-on-prostate-cancer
#13
Natsuo Tomita, Norihito Soga, Yuji Ogura, Jun Furusawa, Hidetoshi Shimizu, Sou Adachi, Hiroshi Tanaka, Daiki Kato, Yutaro Koide, Chiyoko Makita, Hiroyuki Tachibana, Takeshi Kodaira
OBJECTIVE: We aimed to examine the effects of a dose escalation for prostate cancer patients receiving long-term androgen deprivation therapy (ADT). METHODS: A retrospective analysis of 605 patients treated with radiotherapy (RT) and long-term ADT (National Comprehensive Cancer Network criteria-defined intermediate-risk, minimum 10 months; high-risk and very-high-risk, minimum 20 months) was performed. The median ADT time was 31 months. Cox's proportional hazards models were used to compare biochemical disease-free survival (bDFS), clinical relapse-free survival (cRFS) and overall survival (OS) between the ≥70, <78 Gy group and 78 Gy group in a univariate analysis and to assess the effects of the dose escalation on bDFS in a multivariate analysis...
December 5, 2017: British Journal of Radiology
https://www.readbyqxmd.com/read/29151782/salvage-low-dose-rate-brachytherapy-for-recurrent-prostate-cancer-after-external-beam-radiotherapy-results-from-a-single-institution-with-focus-on-toxicity-and-functional-outcomes
#14
F Barbera, L Triggiani, M Buglione, P Ghirardelli, P Vitali, B Caraffini, P Borghetti, D Greco, L Bardoscia, N Pasinetti, L Costa, M Maddalo, B Ghedi, B La Face, S M Magrini
Background/aim: Low dose rate brachytherapy has been used as salvage therapy for locally recurrent prostate cancer (PC) after primary external beam radiation therapy (EBRT), along with surgery and cryotherapy. All these techniques, in particular, when applied to the whole gland, involve a relatively high risk of toxicity and may worsen the patient's quality of life. Our aim is to evaluate the results of whole-gland salvage brachytherapy (SBT) after primary EBRT in terms of toxicity, functional outcomes, and efficacy...
2017: Clinical Medicine Insights. Oncology
https://www.readbyqxmd.com/read/29137875/contribution-of-11-c-choline-pet-ct-in-prostate-carcinoma-biochemical-relapse-with-serum-psa-level-below-1-ng-ml
#15
F J Gómez-de la Fuente, I Martínez-Rodríguez, M de Arcocha-Torres, R Quirce, J Jiménez-Bonilla, N Martínez-Amador, I Banzo
OBJECTIVE: (11)C-choline PET/CT has demonstrated good results in the restaging of prostate cancer (PCa) with high serum prostate specific antigen (PSA), but its use in patients with low serum PSA is controversial. Our aim was to evaluate the contribution of (11)C-choline PET/CT in patients with PCa, biochemical relapse and PSA <1 ng/ml. MATERIAL AND METHOD: Fifty consecutive patients (mean age: 65.9±5.6 years) with biochemical relapse of PCa and serum PSA <1ng/ml were evaluated retrospectively...
November 11, 2017: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29107276/managing-cancer-relapse-after-radical-prostatectomy-adjuvant-versus-salvage-radiation-therapy
#16
REVIEW
Joseph F Rodriguez, Stanley L Liauw, Scott E Eggener
An increasing proportion of men are undergoing radical prostatectomy for locally advanced prostate cancer. More than half of men with adverse pathologic features are expected to experience disease recurrence within 10 years. This article discusses the use of postoperative radiation therapy to decrease this risk. Evidence from 3 randomized trials and multiple retrospective studies indicates that either adjuvant or salvage radiation improve biochemical progression-free survival and may improve overall survival...
November 2017: Urologic Clinics of North America
https://www.readbyqxmd.com/read/29105797/99m-tc-mip-1404-spect-ct-for-the-detection-of-psma-positive-lesions-in-225-patients-with-biochemical-recurrence-of-prostate-cancer
#17
Christian Schmidkonz, Claudia Hollweg, Michael Beck, Julia Reinfelder, Theresa I Goetz, James C Sanders, Daniela Schmidt, Olaf Prante, Tobias Bäuerle, Alexander Cavallaro, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
BACKGROUND: 99m Tc-MIP-1404 (Progenics Pharmaceuticals, Inc., New York, NY) is a novel, SPECT-compatible 99m Tc-labeled PSMA inhibitor for the detection of prostate cancer. We present results of its clinical use in a cohort of 225 men with histologically confirmed prostate cancer referred for workup of biochemical relapse. METHODS: From April 2013 to April 2017, 99m Tc-MIP1404-scintigraphy was performed in 225 patients for workup of PSA biochemical relapse of prostate cancer...
January 2018: Prostate
https://www.readbyqxmd.com/read/29045551/validation-of-a-metastatic-assay-using-biopsies-to-improve-risk-stratification-in-patients-with-prostate-cancer-treated-with-radical-radiation-therapy
#18
S Jain, C A Lyons, S M Walker, S McQuaid, S Hynes, D Mitchell, B Pang, G E Logan, A M McCavigan, D O'Rourke, D McArt, S McDade, I Mills, K M Prise, L A Knight, C J Steele, P W Medlow, V Berge, B Katz, D A Loblaw, D P Harkin, J James, J M O'Sullivan, R D Kennedy, D J Waugh
BackgroundRadiotherapy is an effective treatment for intermediate/high-risk locally-advanced prostate cancer, however, >30% of patients relapse within five years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy (ADT)...
October 10, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29039785/prospective-comparison-of-f-18-choline-pet-ct-scan-versus-axial-mri-for-detecting-bone-metastasis-in-biochemically-relapsed-prostate-cancer-patients
#19
Wouter Huysse, Frédéric Lecouvet, Paolo Castellucci, Piet Ost, Valerie Lambrecht, Carlos Artigas, Marie-Laurence Denis, Kathia De Man, Louke Delrue, Lennart Jans, Aurélie De Bruycker, Filip De Vos, Gert De Meerleer, Karel Decaestecker, Valerie Fonteyne, Bieke Lambert
We compared fluor-18 choline positron emission tomography/computed tomography (PET/CT) and axial skeleton magnetic resonance imaging (MRI) prospectively obtained for the detection of bone metastases in non-castrated patients with biochemically recurrent prostate cancer following primary treatment. PET/CT was performed 45 min post-injection of 3-4 MBq/kg F-18 methyl choline. MRI included T1- and fluid sensitive T2-weighted images of the spine and pelvis. Readers were initially blinded from other results and all scans underwent independent double reading...
October 17, 2017: Diagnostics
https://www.readbyqxmd.com/read/29032014/high-intermediate-prostate-cancer-treated-with-low-dose-rate-brachytherapy-with-or-without-androgen-deprivation-therapy
#20
Tom Pickles, W James Morris, Mira Keyes
PURPOSE: To describe outcomes of men with unfavorable (high-tier) intermediate risk prostate cancer (H-IR) treated with low-dose-rate (LDR) brachytherapy, with or without 6 months of androgen deprivation therapy (ADT). METHODS AND MATERIALS: Patients with H-IR prostate cancer, treated before 2012 with LDR brachytherapy without external radiation are included. Baseline tumor characteristics are described. Outcomes between groups receiving ADT are measured by Phoenix (nadir +2 ng/mL), and threshold 0...
November 2017: Brachytherapy
keyword
keyword
111181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"